NASDAQ:DMAA Drugs Made In America Acquisition Q3 2025 Earnings Report $10.82 -0.03 (-0.28%) As of 09/23/2026 04:00 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Drugs Made In America Acquisition EPS ResultsActual EPS$0.07Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ADrugs Made In America Acquisition Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ADrugs Made In America Acquisition Announcement DetailsQuarterQ3 2025Date11/18/2025TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Drugs Made In America Acquisition Earnings HeadlinesDrugs Made In America Restructures Merger with PAGCSeptember 14, 2026 | tipranks.comDrugs Made In America Acquisition Corp. (DMAA)August 12, 2026 | finance.yahoo.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.September 24 at 1:00 AM | Porter & Company (Ad)Drugs Made In America amends merger agreement termsJuly 20, 2026 | tipranks.comDrugs Made In America Signs Financing and Sponsor DealMarch 27, 2026 | tipranks.comDrugs Made In America Appoints New CFONovember 18, 2025 | tipranks.comSee More Drugs Made In America Acquisition Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Drugs Made In America Acquisition? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Drugs Made In America Acquisition and other key companies, straight to your email. Email Address About Drugs Made In America AcquisitionDrugs Made In America Acquisition (NASDAQ:DMAA) (NASDAQ:DMAA) is a special purpose acquisition company, or SPAC. The company was formed to identify and complete a merger, acquisition, or similar business combination with an operating company. Its stated focus is on businesses in the pharmaceutical, healthcare, and related life sciences sectors, particularly companies involved in the development, manufacturing, or distribution of products in the United States. Unlike an operating pharmaceutical company, Drugs Made In America Acquisition Corp. does not have its own portfolio of drugs, medical products, or healthcare services. As a SPAC, the company’s activities have primarily involved raising capital through a public offering, evaluating potential acquisition targets, and pursuing a business combination. Information about a completed transaction, an operating subsidiary, geographic operations beyond its U.S.-focused investment mandate, or a detailed management history is limited.View Drugs Made In America Acquisition ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Energy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock?Thor Industries Is Boring—And That May Be Its Biggest AdvantageAutoZone Shifts Gears, On Track to Reverse Course and Price RecoveryMeta’s Muse Highlights Arm’s Growing Role in AI InfrastructureOld Dogs, New Tech: 3 Legacy Stocks Powering the AI Boom Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
